137 related articles for article (PubMed ID: 11290606)
1. The combination of chemotherapy and systemic immunotherapy with soluble B7-immunoglobulin G leads to cure of murine leukemia and lymphoma and demonstration of tumor-specific memory responses.
Runyon K; Lee K; Zuberek K; Collins M; Leonard JP; Dunussi-Joannopoulos K
Blood; 2001 Apr; 97(8):2420-6. PubMed ID: 11290606
[TBL] [Abstract][Full Text] [Related]
2. Gene immunotherapy in murine acute myeloid leukemia: granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines.
Dunussi-Joannopoulos K; Dranoff G; Weinstein HJ; Ferrara JL; Bierer BE; Croop JM
Blood; 1998 Jan; 91(1):222-30. PubMed ID: 9414288
[TBL] [Abstract][Full Text] [Related]
3. CD8+ T cells activated during the course of murine acute myelogenous leukemia elicit therapeutic responses to late B7 vaccines after cytoreductive treatment.
Dunussi-Joannopoulos K; Krenger W; Weinstein HJ; Ferrara JL; Croop JM
Blood; 1997 Apr; 89(8):2915-24. PubMed ID: 9108412
[TBL] [Abstract][Full Text] [Related]
4. Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy.
Kanwar JR; Shen WP; Kanwar RK; Berg RW; Krissansen GW
J Natl Cancer Inst; 2001 Oct; 93(20):1541-52. PubMed ID: 11604477
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and mechanisms of action of rmB7.2-Ig as an antitumor agent in combination with Adriamycin and Cytoxan chemotherapy.
Zhou H; Sequeira M; Goad ME; Erickson J; Wong A; Clark E; Dunussi-Joannopoulos K; Li RC; Friedrich S; Hayes LL; Wolf SF
Clin Immunol; 2001 Dec; 101(3):303-14. PubMed ID: 11726223
[TBL] [Abstract][Full Text] [Related]
6. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
[TBL] [Abstract][Full Text] [Related]
7. The combination of chemotherapy and systemic immunotherapy and the concept of cure in murine leukemia and lymphoma.
Dunussi-Joannopoulos K
Leuk Lymphoma; 2002 Nov; 43(11):2075-82. PubMed ID: 12533031
[TBL] [Abstract][Full Text] [Related]
8. The role of B7 costimulation by murine acute myeloid leukemia in the generation and function of a CD8+ T-cell line with potent in vivo graft-versus-leukemia properties.
Boyer MW; Vallera DA; Taylor PA; Gray GS; Katsanis E; Gorden K; Orchard PJ; Blazar BR
Blood; 1997 May; 89(9):3477-85. PubMed ID: 9129056
[TBL] [Abstract][Full Text] [Related]
9. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein.
Huang X; Wong MK; Yi H; Watkins S; Laird AD; Wolf SF; Gorelik E
Cancer Res; 2002 Oct; 62(20):5727-35. PubMed ID: 12384531
[TBL] [Abstract][Full Text] [Related]
10. Negative effect of CTLA-4 on induction of T-cell immunity in vivo to B7-1+, but not B7-2+, murine myelogenous leukemia.
LaBelle JL; Hanke CA; Blazar BR; Truitt RL
Blood; 2002 Mar; 99(6):2146-53. PubMed ID: 11877291
[TBL] [Abstract][Full Text] [Related]
11. Targeting of a B7-1 (CD80) immunoglobulin G fusion protein to acute myeloid leukemia blasts increases their costimulatory activity for autologous remission T cells.
Notter M; Willinger T; Erben U; Thiel E
Blood; 2001 May; 97(10):3138-45. PubMed ID: 11342441
[TBL] [Abstract][Full Text] [Related]
12. Combined antiangiogenic and immune therapy of prostate cancer.
Huang X; Raskovalova T; Lokshin A; Krasinskas A; Devlin J; Watkins S; Wolf SF; Gorelik E
Angiogenesis; 2005; 8(1):13-23. PubMed ID: 16132614
[TBL] [Abstract][Full Text] [Related]
13. Potent activity of soluble B7-IgG fusion proteins in therapy of established tumors and as vaccine adjuvant.
Sturmhoefel K; Lee K; Gray GS; Thomas J; Zollner R; O'Toole M; Swiniarski H; Dorner A; Wolf SF
Cancer Res; 1999 Oct; 59(19):4964-72. PubMed ID: 10519410
[TBL] [Abstract][Full Text] [Related]
14. Induction of tumor regression by administration of B7-Ig fusion proteins: mediation by type 2 CD8+ T cells and dependence on IL-4 production.
Yamaguchi N; Hiraoka S; Mukai T; Takeuchi N; Zhou XY; Ono S; Kogo M; Dunussi-Joannopoulos K; Ling V; Wolf S; Fujiwara H
J Immunol; 2004 Feb; 172(3):1347-54. PubMed ID: 14734709
[TBL] [Abstract][Full Text] [Related]
15. Active antitumor immunotherapy, with or without B7-mediated costimulation, increases tumor progression in an immunogenic murine T cell lymphoma model.
Raes G; Van Ginderachter J; Liu YQ; Brys L; Thielemans K; De Baetselier P; Geldhof A
Cancer Immunol Immunother; 1998 Jan; 45(5):257-65. PubMed ID: 9439649
[TBL] [Abstract][Full Text] [Related]
16. Role of B7-1 in mediating an immune response to myeloid leukemia cells.
Matulonis UA; Dosiou C; Lamont C; Freeman GJ; Mauch P; Nadler LM; Griffin JD
Blood; 1995 May; 85(9):2507-15. PubMed ID: 7537118
[TBL] [Abstract][Full Text] [Related]
17. Induction of therapeutic T-cell immunity by tumor targeting with soluble recombinant B7-immunoglobulin costimulatory molecules.
Moro M; Gasparri AM; Pagano S; Bellone M; Tornaghi P; Veglia F; Corti A; Casorati G; Dellabona P
Cancer Res; 1999 Jun; 59(11):2650-6. PubMed ID: 10363988
[TBL] [Abstract][Full Text] [Related]
18. Regulation of CD80/B7-1 and CD86/B7-2 molecule expression in human primary acute myeloid leukemia and their role in allogenic immune recognition.
Costello RT; Mallet F; Sainty D; Maraninchi D; Gastaut JA; Olive D
Eur J Immunol; 1998 Jan; 28(1):90-103. PubMed ID: 9485189
[TBL] [Abstract][Full Text] [Related]
19. Lentiviral vectors for efficient delivery of CD80 and granulocyte-macrophage- colony-stimulating factor in human acute lymphoblastic leukemia and acute myeloid leukemia cells to induce antileukemic immune responses.
Stripecke R; Cardoso AA; Pepper KA; Skelton DC; Yu XJ; Mascarenhas L; Weinberg KI; Nadler LM; Kohn DB
Blood; 2000 Aug; 96(4):1317-26. PubMed ID: 10942373
[TBL] [Abstract][Full Text] [Related]
20. Comparable in vivo efficacy of CD28/B7, ICOS/GL50, and ICOS/GL50B costimulatory pathways in murine tumor models: IFNgamma-dependent enhancement of CTL priming, effector functions, and tumor specific memory CTL.
Zuberek K; Ling V; Wu P; Ma HL; Leonard JP; Collins M; Dunussi-Joannopoulos K
Cell Immunol; 2003 Sep; 225(1):53-63. PubMed ID: 14643304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
